Volunteer for NIAID-funded clinical studies related to immune tolerance on ClinicalTrials.gov.
NIAID, along with the National Institute of Diabetes and Digestive and Kidney Diseases and the Juvenile Diabetes Research Foundation International, cosponsors the Immune Tolerance Network (ITN), an international consortium of more than 80 investigators in the United States, Canada, Europe, and Australia dedicated to the clinical evaluation of novel, tolerance-inducing therapies for autoimmune diseases, asthma and allergic diseases, and transplant rejection. ITN conducts integrated studies on the mechanisms that underlie immune tolerance and develops markers and assays to measure the induction, maintenance, and loss of tolerance in humans. The network has established several state-of-the-art core facilities and has supported 18 approved clinical protocols as well as several additional studies of the immune mechanisms involved in tolerance.
ITN is currently involved in the following areas of clinical research:
Examples of active ITN clinical research studies include
Tolerance assays—tests and procedures to monitor patient responses to tolerance therapies—are critically needed to better evaluate tolerance-inducing therapies during and after clinical trials. ITN has therefore established a set of core laboratories to develop assays for the induction, maintenance, or loss of immune tolerance. These core facilities carry out microarray analyses of gene expression, develop analytic tools for clinical and scientific datasets from ITN-sponsored trials, and conduct enzyme-linked immunospot (ELISPOT) assay analyses of protein expression and cellular assays for T cell reactivity.
Examples of current ITN efforts to develop mechanistic assays include
More information on ITN’s mission and research is available at www.immunetolerance.org.
back to top
Last Updated March 28, 2006